RNA sequencing of pre-treatment biopsy sampless from BrighTNess phase III study (AFT-04)

BrighTNess was a phase III, multicenter, randomized, double-blind, placebo-controlled study that enrolled stage II/III TNBC patients to receive neoadjuvant chemotherapy with paclitaxel followed by doxorubicin/cyclophosphamid (AC), or the same plus carboplatin or carboplatin plus the PARP inhibitor veliparib concurrent with paclitaxel. Whole transcriptome RNA sequencing (RNAseq) was performed on pre-treatment research biopsies. Whole transcriptome RNA sequencing (RNAseq) was performed on pretreatment research biopsies *** Submitter declares that they do not have permission to deposit the raw data due to patient privacy concerns ***

BrighTNess为一项Ⅲ期多中心随机双盲安慰剂对照临床试验，招募了Ⅱ/Ⅲ期三阴性乳腺癌（triple-negative breast cancer, TNBC）患者，受试者可接受三种新辅助化疗方案：紫杉醇序贯多柔比星/环磷酰胺（AC方案）；紫杉醇序贯AC方案联合卡铂；或在紫杉醇化疗期间同步联用卡铂与多聚ADP核糖聚合酶（PARP）抑制剂维利帕尼（veliparib）。研究人员对受试者治疗前的科研活检组织样本实施了全转录组RNA测序（RNAseq）。研究人员对受试者治疗前的科研活检组织样本实施了全转录组RNA测序（RNAseq）。*** 提交者声明，因患者隐私保护问题，无权上传该研究的原始数据 ***

搜集汇总

背景与挑战

背景概述

该数据集来自BrighTNess III期临床试验（AFT-04），包含482例II/III期三阴性乳腺癌（TNBC）患者预处理活检样本的全转录组RNA测序（RNA-seq）数据，用于比较不同新辅助化疗方案（如紫杉醇、卡铂和PARP抑制剂veliparib）的疗效。数据使用Illumina HiSeq 3000平台生成，但受患者隐私限制，仅提供处理后的表达数据文件，未包含原始测序数据。